Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an update.
Lumos Diagnostics has partnered with PRO-spectus to enhance market access and reimbursement for its FebriDx® test in the US. This collaboration aims to secure coverage from private insurance payors, which dominate the US health insurance market, thereby increasing patient access to FebriDx®. The partnership will provide strategic and operational services to healthcare providers, facilitating reimbursement and adoption of FebriDx®, ultimately improving patient outcomes and addressing antimicrobial resistance.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid point-of-care diagnostic test technology to aid healthcare professionals in accurately diagnosing and managing medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.
Average Trading Volume: 5,118,398
Technical Sentiment Signal: Buy
Current Market Cap: A$73.36M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.